logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Growth factors in tussues of ovarian cancer at various stages

[Oncology]
Oleg Kit; Elena Frantsiyants; Tatyana Moiseenko; Ekaterina Verenikina; Natalia Cheryarina; Larisa Kozlova; Yulia Pogorelova;

Levels of endothelial growth factor VEGF-A and its receptor sVEGF-R1, epidermal growth factor EGF and its receptor sEGF-R and tumor necrosis factor TNF-α were studied in tissue samples obtained from 76 patients with epithelial ovarian cancer (serous cystadenocarcinoma) and 47 patients with benign ovarian tumors (cystadenoma). 20 ovarian tissue samples obtained during the surgery for hysteromyoma were used as conditionally intact tissue. Development of epithelial ovarian cancer was revealed to be accompanied by a progressive activation of angiogenic activity in tumor tissue due to the increased expression of the free forms of growth factors: first VEGF and then EGF, and maintained by the increased TNF-α level. The results obtained for the contralateral ovaries are of special interest, as they allow lifting the veil on pathogenesis of ovarian malignant transformation.

Download

References:
1. Arhipova O. E., Chernogubova E. A., Tarasov V. A., Litanskaja N. V., Kit O. I., Eremeeva A. A., Matishov D. G. Vestnik Juzhnogo nauchnogo centra RAN. – Bulletin of the southern scientific center of RAS. 2013;9(3):7-14.
2. Baron A. T., Wilken J. A., Haggstrom D. E., Goodrich S. T., Maihle N. J. IDrugs. 2009;12(5):302-308.
3. Bertazza L., Mocellin S. Front Biosci. 2008;13:2736- 2743. doi: 10.2741-2881
4. Bhaskari J., Shilpa V., Rahul B., Chennagiri S. P., Venketeshiahi R. P., Gawari R., Krishnamurthy L. PLoS One. 2015;10(7):131-190.
5. Chen H., Xie X., Chen W. Gynecol. Oncol. 2004;94(3):630- 635.
6. Crawford J., Ferrara N. Studies of cells and tissues. 2009; 335(1):261-269.
7. Duhoux François P., Machiels J.-P. J. Оncology. 2010;372:547.
8. Huang J., Hu W., Sood A. K. Cancer Biomark. 2010-2011; 8(4-5): 231-251.
9. Jammal M. P., Da silva A. A., Filho A. M., De castro E., Adad S. J., Murta E. F. C., Nomelini R. S. Oncol Lett. 2015;9(2):979-983.
10. Kolomeyevskaya N., Eng K. H., Khan A. N., Grzankowski K. S., Singel K. L., Moysich K., Segal B. H. Gynecol. oncology. 2015;138(2):352-357.
11. Maihle N. J., Baron A. T., Barrett B. A., Boardman C. H., Christensen T. A., Cora E. M., Faupel-Badger J. M., Greenwood T., Juneja S. C., Lafky J. M., Lee H., Reiter J. L., Podratz K. C. Cancer Treat. Res. 2002;107:247-258.
12. Martin L., Schilder N. J. Clinic. Oncology. 2007;25(20):2894-2901.
13. Masumi Moghaddam S., Amini A., Morris D. L.,Pourgholami M. H. Cancer Met. Rev. 2012;31(1-2):143- 162.
14. Nicholson R., Gee J. I. M., Harper M. E. Eur. J. Cancer. 2001;37(4):9-15.
15. Qiu X., Cheng J. C., Clausen C., Chang H. M., Fan Q., Leung P. C. J. Cell. Physiol. 2016;231(1):111-119.
16. Ravikumar G., Crasta J. A. J. Cancer. 2013;2(2):87-90.
17. Schumacher J. J., Dings R. P., Cosin J., Subramanian I. V., Auersperg N., Ramakrishnan S. Cancer Research. 2007;67(8):3683-3690.
18. Szlosarek P. W., Grimshaw M. J., Kulbe H., Wilson J. L., Wilbanks G. D., Burke F., Balkwill F. R. Mol. Cancer Ther. 2006;5(2):382-390.
19. Szlosarek P. W., Grimshaw M. J., Wilbanks G. D., Hagemann T., Wilson J. L., Burke F., Stamp G., Balkwill F. R. Int. J. Cancer. 2007;121(1):6-11.
20. Vaidya A. P., Parnes A. D., Seiden M. V. Curr. Treat. Options Oncol. 2005;6(2):103-114.

Keywords: ovarian cancer, growth factors, contralateral ovary, VEGF-А, sVEGF-R1, EGF, sEGF-R, TNF-α


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy